Fructus lycii oligosaccharide alleviates acute liver injury via PI3K/Akt/mTOR pathway

Immunol Res. 2024 Apr;72(2):271-283. doi: 10.1007/s12026-023-09431-y. Epub 2023 Nov 30.

Abstract

Regulating the immune-environment is essential for treating acute liver injury (ALI). However, the deficiency of an effective immune balancer restricted progress. Herein, we reported an oligosaccharide from Fructus lycii oligosaccharide (FLO). To investigate the effects of FLO, we adopted primary macrophages and LO2 for experiments in vitro. In vivo, we assessed the influence of FLO in ALI with histochemical staining and enzyme indicators detection. Following that, we clarified the underlying mechanisms using western blotting and immunofluorescence. Our results indicated that FLO (100 μg/mL) showed apparent inflammatory reversal effects by shifting the phenotype of macrophages from M1 to M2 without causing any cytotoxicity. Furthermore, CCl4-induced mice were significantly improved by FLO intragastric administration. Meanwhile, PI3K/AKT/mTOR pathway was confirmed for the up-regulation of IL-10 via M2 polarization of macrophages. Collectively, our findings highlight the beneficial effects of FLO on ALI therapy via M1 to M2 macrophage conversion.

Keywords: Acute liver injury (ALI); CCl4; Fructus lycii oligosaccharide (FLO); Macrophage; PI3K/AKT/mTOR pathway.

MeSH terms

  • Animals
  • Liver
  • Macrophages
  • Mice
  • Phosphatidylinositol 3-Kinases*
  • Proto-Oncogene Proteins c-akt*
  • TOR Serine-Threonine Kinases / metabolism
  • TOR Serine-Threonine Kinases / pharmacology

Substances

  • Proto-Oncogene Proteins c-akt
  • Phosphatidylinositol 3-Kinases
  • TOR Serine-Threonine Kinases